Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids

✍ Scribed by Kevin P. O'Boyle; Yuexian Wang; Edward L. Schwartz; Donna Lee Regl; Avi Einzig; Janice P. Dutcher; Peter H. Wiernik; Susan Band Horwitz

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 133 KB
• Volume: 79
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19970301)79:5<1022::aid-cncr20>3.0.co;2-2

✦ Synopsis

an immunoradiometric assay (IRMA), in which 125 I-labeled antibody was used, and in a more conventional tritiated radioimmunoassay (RIA),in which 3 H-paclitaxel Departments of Oncology and Molecular Pharwas used. macology, Montefiore Medical Center/Albert RESULTS. Both radioimmunoassays detected levels of paclitaxel in sera that were Einstein Cancer Center, Bronx, New York. comparable to those observed with HPLC. However, the IRMA was the most sensitive. Only the IRMA was able to detect low levels of paclitaxel in cerebrospinal fluid after paclitaxel infusion and in sera 3 weeks after infusion. Both the IRMA and RIA methods were able to detect paclitaxel in ascitic and pleural fluids.

CONCLUSIONS.

Monitoring paclitaxel levels reliably in sera and other bodily fluids is possible with these radioimmunoassays and may be of value in predicting and preventing toxicity and optimizing paclitaxel treatments.